UNSPSC 51142315: Naloxone hydrochloride

This classification denotes a narcotic antagonist with the molecular formula C19H21NO4.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier F850569PQR, chemically known as 17-allyl-4,5alpha-epoxy-3,14-dihydroxymorphinan-6-one hydrochloride but more generally known as naloxone hydrochloride, which bears US NIH Compound Identifier 5464092. European Medicines Agency schedules Naloxone hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03382MIG.

UNSPSC 51142315 Naloxone hydrochloride is a Commodity code covering the procurement of naloxone products for emergency opioid overdose response and related community health initiatives by state and local public bodies. State and local governments are purchasing naloxone in two distinct procurement modes: as finished pharmaceutical inventory for direct dispensing and stockpiling by county health departments and community health programs, and as a bundled component within broader substance abuse education and harm reduction service contracts. The code sees activity from county health agencies and special-purpose health programs rather than school districts or transit authorities; issuing bodies include health-focused county agencies and regional health consortia operating under public-health mandates to reduce opioid-related mortality.

Recent opportunities span Florida, California, Texas, and Minnesota. Seminole County, Florida issued IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to its Community Health Building in Sanford, requiring electronic bid submission and fixed pricing with a two-year initial term and one-year renewal option. The County of Orange Health Care Agency in California posted RFP for Fentanyl Education and Naloxone Training Services in June 2026 with a total program budget of $700,000 for the initial contract year, requesting comprehensive education and training delivery across diverse populations with Phase 1 written proposal scoring (maximum 900 points) and potential Phase 2 oral interviews; the RFP offers local small business and Disabled Veteran Business Enterprise set-asides and preferences, with proposals due April 9, 2026. Texas Health and Human Services Commission issued RFI HHS0017013 in April 2026 as exploratory market intelligence on direct-to-manufacturer prescription fulfillment, not a formal competitive solicitation. Minnesota's MMCAP cooperative purchasing vehicle posted an RFP in January 2026 for generic multi-source pharmaceuticals and OTC products available through authorized wholesalers with proposals due March 26, 2026 and contracts effective July 1, 2026, weighted 75 percent on price competitiveness.